Cargando…
Bioinspired Platelet-like Nanovector for Enhancing Cancer Therapy via P-Selectin Targeting
Cancer is a major threat to the health of humans. Recently, various natural products including curcumin (CCM) have attracted enormous interest for efficacious cancer therapy. However, natural therapeutic agents still encounter certain challenges such as rapid clearance, low bioavailability, and poor...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9783179/ https://www.ncbi.nlm.nih.gov/pubmed/36559108 http://dx.doi.org/10.3390/pharmaceutics14122614 |
_version_ | 1784857516130172928 |
---|---|
author | Wan, Shengli Wu, Yuesong Fan, Qingze Yang, Gang Hu, Haiyang Tima, Singkome Chiampanichayakul, Sawitree Anuchapreeda, Songyot Wu, Jianming |
author_facet | Wan, Shengli Wu, Yuesong Fan, Qingze Yang, Gang Hu, Haiyang Tima, Singkome Chiampanichayakul, Sawitree Anuchapreeda, Songyot Wu, Jianming |
author_sort | Wan, Shengli |
collection | PubMed |
description | Cancer is a major threat to the health of humans. Recently, various natural products including curcumin (CCM) have attracted enormous interest for efficacious cancer therapy. However, natural therapeutic agents still encounter certain challenges such as rapid clearance, low bioavailability, and poor tumor targeting. Recently, the platelet membrane (PM) camouflaged nanoparticle has provided a promising solution for cancer targeting therapy. Nevertheless, only limited efforts have been dedicated to systematically explore the mechanism of affinity between PM bioinspired nanoparticles and various tumor cells. Herein, a CCM-encapsulated platelet membrane biomimetic lipid vesicle (CCM@PL) with a size of 163.2 nm, zeta potential of −31.8 mV and encapsulation efficiency of 93.62% was developed. The values of the area under the concentration-time curve and mean residence time for CCM@PL were 3.08 times and 3.04 times those of CCM, respectively. Furthermore, this PM biomimetic carrier showed an excellent affinity against Huh-7, SK-OV-3 and MDA-MB-231 cell lines due to the biomolecular interaction between P-selectin on the PM and tumoral CD44 receptors. In addition, CCM@PL displayed enhanced cytotoxicity compared with free CCM and the synthetic formulation. Overall, our results suggest that this developed PM biomimetic lipid nanovector has great potential for targeted cancer treatment and natural components delivery. |
format | Online Article Text |
id | pubmed-9783179 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-97831792022-12-24 Bioinspired Platelet-like Nanovector for Enhancing Cancer Therapy via P-Selectin Targeting Wan, Shengli Wu, Yuesong Fan, Qingze Yang, Gang Hu, Haiyang Tima, Singkome Chiampanichayakul, Sawitree Anuchapreeda, Songyot Wu, Jianming Pharmaceutics Article Cancer is a major threat to the health of humans. Recently, various natural products including curcumin (CCM) have attracted enormous interest for efficacious cancer therapy. However, natural therapeutic agents still encounter certain challenges such as rapid clearance, low bioavailability, and poor tumor targeting. Recently, the platelet membrane (PM) camouflaged nanoparticle has provided a promising solution for cancer targeting therapy. Nevertheless, only limited efforts have been dedicated to systematically explore the mechanism of affinity between PM bioinspired nanoparticles and various tumor cells. Herein, a CCM-encapsulated platelet membrane biomimetic lipid vesicle (CCM@PL) with a size of 163.2 nm, zeta potential of −31.8 mV and encapsulation efficiency of 93.62% was developed. The values of the area under the concentration-time curve and mean residence time for CCM@PL were 3.08 times and 3.04 times those of CCM, respectively. Furthermore, this PM biomimetic carrier showed an excellent affinity against Huh-7, SK-OV-3 and MDA-MB-231 cell lines due to the biomolecular interaction between P-selectin on the PM and tumoral CD44 receptors. In addition, CCM@PL displayed enhanced cytotoxicity compared with free CCM and the synthetic formulation. Overall, our results suggest that this developed PM biomimetic lipid nanovector has great potential for targeted cancer treatment and natural components delivery. MDPI 2022-11-26 /pmc/articles/PMC9783179/ /pubmed/36559108 http://dx.doi.org/10.3390/pharmaceutics14122614 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Wan, Shengli Wu, Yuesong Fan, Qingze Yang, Gang Hu, Haiyang Tima, Singkome Chiampanichayakul, Sawitree Anuchapreeda, Songyot Wu, Jianming Bioinspired Platelet-like Nanovector for Enhancing Cancer Therapy via P-Selectin Targeting |
title | Bioinspired Platelet-like Nanovector for Enhancing Cancer Therapy via P-Selectin Targeting |
title_full | Bioinspired Platelet-like Nanovector for Enhancing Cancer Therapy via P-Selectin Targeting |
title_fullStr | Bioinspired Platelet-like Nanovector for Enhancing Cancer Therapy via P-Selectin Targeting |
title_full_unstemmed | Bioinspired Platelet-like Nanovector for Enhancing Cancer Therapy via P-Selectin Targeting |
title_short | Bioinspired Platelet-like Nanovector for Enhancing Cancer Therapy via P-Selectin Targeting |
title_sort | bioinspired platelet-like nanovector for enhancing cancer therapy via p-selectin targeting |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9783179/ https://www.ncbi.nlm.nih.gov/pubmed/36559108 http://dx.doi.org/10.3390/pharmaceutics14122614 |
work_keys_str_mv | AT wanshengli bioinspiredplateletlikenanovectorforenhancingcancertherapyviapselectintargeting AT wuyuesong bioinspiredplateletlikenanovectorforenhancingcancertherapyviapselectintargeting AT fanqingze bioinspiredplateletlikenanovectorforenhancingcancertherapyviapselectintargeting AT yanggang bioinspiredplateletlikenanovectorforenhancingcancertherapyviapselectintargeting AT huhaiyang bioinspiredplateletlikenanovectorforenhancingcancertherapyviapselectintargeting AT timasingkome bioinspiredplateletlikenanovectorforenhancingcancertherapyviapselectintargeting AT chiampanichayakulsawitree bioinspiredplateletlikenanovectorforenhancingcancertherapyviapselectintargeting AT anuchapreedasongyot bioinspiredplateletlikenanovectorforenhancingcancertherapyviapselectintargeting AT wujianming bioinspiredplateletlikenanovectorforenhancingcancertherapyviapselectintargeting |